Paracoccidioidomycosis (South American blastomycosis) is the most widespread systemic mycosis in Latin America (4) . Imported cases are reported in the United States (8, 15) . The fungal phase in vivo is a yeast. The disease appears in two forms, as an acute or chronic pulmonary disease or disseminated, with involvement of the mucocutaneous tissues, lymphoreticular system, and other organs (19) . It is believed that the active disease is progressive and, without treatment, ultimately fatal (15, 17) . The initial therapeutic agents used to treat it were sulfa drugs. However, even with a criterion of partial inhibition, in vitro resistance of the etiological agent (Paracoccidioides brasiliensis) to achievable serum concentrations is not uncommon (16) , and efficacy could not be demonstrated in an animal model (24) . Although clinical experience has been obtained largely with the sulfa drugs, these agents are now thought to be suppressive at best in most cases because of slow clinical responses, failures to respond, and relapses after apparently successful therapy (20, 23) . Amphotericin B and miconazole produce high response rates, but they must be given intravenously and have undesirable side effects (25) , and relapse is also a problem (23, 26) .
Recent reports of success with ketoconazole are encouraging (21) ; however, although ketoconazole can, like the sulfa drugs, be given orally, it is more expensive.
Because a synergistic interaction is so commonly demonstrated between sulfa drugs and trimethoprim, side effects with the combination are few, and oral therapy is possible (22) , the present study of the in vitro interaction of these agents with P. brasiliensis was undertaken.
The strains used were clinical isolates from Colombian patients (21, 26 (18) , was used to grow the inoculum and in the assays. Trimethoprim and sulfamethoxazole in commercially available combination tablets provide peak serum levels in the ratio of 1:20, respectively (22) . As this ratio may not provide optimal synergistic interaction for some organisms, e.g., Nocardia (3), ratios of 1:5 and 1:2 were also studied. Twofold dilutions from a starting concentration of 1,600 or 2,000 ,ug of each drug per ml were used in different runs. Each in vitro determination was performed two to four times, and in no case did the result vary by more than two dilutions from the highest to the lowest value in all studies. The mean value of the multiple assays is given in each case, and if that value fell between dilutions, the arithmetic mean is given. Incubation for 5 to 7 days was required before growth was clearly evident in the control (drugfree) tubes. Table 1 shows the results of MIC determinations with sulfamethoxazole alone, trimethoprim alone, and the combination in various propor- a S, Sulfamethoxazole; T, trimethoprim. As the MIC for S was off-scale (>2,000 ,ug/ml) for three isolates, an arbitrary value of 4,000 ,ug/ml was used for these FIC calculations, shown by a < symbol.
tions. Several findings were apparent. (i) Three offour and four offour isolates were resistant to achievable serum concentrations of sulfamethoxazole and trimethoprim, respectively. (ii) Marked synergy was noted with the three strains resistant to sulfamethoxazole at all ratios tested. (iii) In two instances, the 5:1 ratio gave the most impressive results; in a third (strain 263), the 20:1 ratio was best, but only slightly better than 5:1 was; in the other, susceptibility to sulfamethoxazole dominated the results, and the isolate appeared indifferent to the effect of the small amounts of trimethoprim at that end of the dilution series. (iv) Each isolate was susceptible to at least one combination at concentrations achievable in serum with higher doses of the drugs (11), doses that have been utilized in other human diseases (1, 7, 12) .
With regard to the first of these findings, only isolate 263 came from a patient previously treated with sulfa. This patient relapsed after apparent response earlier to sulfa. The third finding discussed above was most easily understood by calculation of a fractional inhibitory concentration (FIC) index, in a fashion similar to that described previously (6) , and this allowed comparison with the data obtained previously with these drugs on bacteria (5) ( Table 2 ). The FIC for each drug equals the MIC of the drug alone divided into its concentration in a particular combination at the lowest concentrations of that combination inhibiting growth, and the index equals the sum of the two FICs. By this formulation, an index of 1.0 represents an additive effect, >2.0 shows antagonism, and <1.0 shows synergy. Examination of Table 2 thus readily reveals the marked synergy for three strains.
When the IC50 was determined, resistance to trimethoprim alone was still evident (Table 3) for three strains, but resistance to sulfamethoxazole alone would not have been as evident by this parameter. This is of interest because of the convention in in vitro sulfa susceptibility testing of using 80% inhibition of bacteria as a cutoff, with the implication that there may be a large discrepancy between the concentrations required for partial inhibition and complete inhibition (27) . Presumably in relation to our finding of inhibition with sulfamethoxazole, the IC50 of the drugs in combination was no more striking, with inhibition demonstrated at dilutions of approximately 1.0 ,ug/ml or less of both drugs or, for 
